ArticleMetabolites2026
Systemic Biomarkers Do Not Discriminate Psoriasis, Atopic Dermatitis and Their Coexistence: An Equivalence-Based Cross-Sectional Analysis of 160,782 UK Biobank Participants.
Article in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
BACKGROUND/
objectivesPsoriasis and atopic dermatitis have been conceived as opposite immunological poles, yet molecular overlap and clinically recognised coexistence challenge this dichotomy. We sought to adjudicate among three architectures: overlap with no discriminating systemic signature, a shared inflammatory and metabolic continuum with additive coexistence, and distinct phenotypes with synergy.
methodsCross-sectional analysis of a selected UK Biobank subsample of 160,782 participants, classified by International Classification of Diseases, 10th revision codes L40 and L20 as control, isolated atopic dermatitis (
resultsEffect sizes were negligible for 46 of 48 contrasts against a comorbidity-free comparator, and 38 of 48 met formal equivalence. None of the 16 interaction terms survived false discovery rate control. Multivariate separation was detectable but explained 0.6% of dispersion, classification reached an area under the curve of 0.57, and latent classes bore no correspondence to clinical diagnosis. When cardiometabolic exclusions were applied symmetrically to all four groups, every contrast met equivalence, and the ordering of the dominant factor did not persist. Polygenic risk scores confirmed that the coded groups carry the expected genetic architecture.
conclusionsWithin the systemic biomarkers evaluated these conditions are not discriminable, and coexistence is not an emergent phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.